Cart
sales@molnova.com
ILK-IN-3
CAS No. 6975-75-3
ILK-IN-3( —— )
Catalog No. M22072 CAS No. 6975-75-3
ILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 67 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 101 | In Stock |
|
| 25MG | 202 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 449 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameILK-IN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.
-
DescriptionILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.(In Vitro):ILK-IN-3 (compound 4, 10 μM) inhibits DYRK1, GSK3α/β, CDK5/p25 kinase activity to 17%, 51%, 47%, 95%, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number6975-75-3
-
Formula Weight232.24
-
Molecular FormulaC10H12N6O?
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (358.81 mM)
-
SMILESCOC1=CC=C(C=C1)N=NC2=C(NN=C2N)N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jessica Kalra, et al. Validating the Use of a Luciferase Labeled Breast Cancer Cell Line, MDA435LCC6, as a Means to Monitor Tumor Progression and to Assess the Therapeutic Activity of an Established Anticancer Drug, Docetaxel (Dt) Alone or in Combination With the ILK Inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1;11(9):826-38.
molnova catalog
related products
-
ATN-161 trifluoroace...
ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist that inhibits angiogenesis and growth of liver metastases in a murine model.The combination of ATN-161 plus 5-FU significantly reduces tumor cell proliferation compared to control and single-agent therapy.
-
BIO-7662
A potent, highly selective α4β1 integrin antagonist with Kd of <10 pM.
-
OSU-T315
A novel potent, orally active ILK (integrin-linked kinase) inhibitor with IC50 of 0.6 uM.
